Immunotoxicotherapy: Present status and future trends

References

• Vale J. A. The epidemiology of acute poisoning. Acta Pharmacol. Toxicol. 1977; 41: 443–458
   PubMedGoogle Scholar
• Bismuth C., Scherrmann J. M., Garnier R., Baud F. J., Pontal P. G. Elimination of paraquat. Human Toxicol. 1987; 6: 63–67
   PubMedGoogle Scholar
• Bismuth C., Baud F., Leporc P., Naguib S., Sato S. Epidémiologie et cout des intoxications aiguës hospitalisées, à propos de 1000 cas. Rev. Franc. Lab. 1985; 140: 106–110
   Google Scholar
• Russel F. E. Snake venom poisoning. Scholium International, Inc, Great Neck, New York 1983
   Google Scholar
• Colburn W. A. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metab. Rev. 1980; 11: 223–262
   PubMed Web of Science ®Google Scholar
• Smith T. W., Haber E., Yeatman L., Butler V. P. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N. Engl. J. Med. 1976; 294: 797–800
   PubMed Web of Science ®Google Scholar
• Sullivan J. B. Immunotherapy in the poisoned patient. Overview of present applications and future trends. Med. Toxicol. 1986; 1: 47–60
   PubMedGoogle Scholar
• Erlanger B. P. Principles and methods for the preparation of drug protein conjugates for immunological studies. Pharmacol. Rev. 1973; 25: 271–280
   PubMed Web of Science ®Google Scholar
• Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Butler V. P., Beiser S. M. Antibodies to small molecules: biological and clinical implications. Adv. Immunol. 1973; 17: 255–310
   PubMedGoogle Scholar
• Hochman J., Inbar D., Givol D. An active antibody fragment (Fv) composed of the variable portions of heavy and light chains. Biochemistry 1973; 12: 1130–1135
   PubMed Web of Science ®Google Scholar
• Butler V. P. Antibodies as specific antagonists of toxins, drugs and hormones. Pharmacol. Rev. 1982; 34: 109–114
   PubMed Web of Science ®Google Scholar
• Wright A. F., Green T. P., Daley-Yates P., Smith L. L. Monoclonal antibody does not protect mice from paraquat toxicity (Abstract). III World Congress of the World Federation of Association of Clinical Toxicology and Poison Control Centres, Brussels, August 27–30, 1986
   Google Scholar
• Cadot R., Descotes J., Grenot C., Cuilleron C. Y., Evreux J. C. Increased plasma paraquat levels in intoxicated mice following antiparaquat F(ab′)2 treatment. J. Immunopharmacol. 1985; 7: 467–477
   PubMed Web of Science ®Google Scholar
• Wenger T. L., Butler V. P., Haber E., Smith T. W. Treatment of 63 severely digitalis-toxic patients with digoxin specific antibody fragments. J. Am. Coll. Cardiol. 1985; 5: 118–123
   PubMed Web of Science ®Google Scholar
• Smolarz A., Roesch E., Lenz H., Neubert P., Abshagen U. Digoxin specific antibody fragments (Fab) in 34 cases of severe digitalis intoxication. Clin. Toxicol. 1985; 23: 327–340
   Web of Science ®Google Scholar
• Scherrmann J. M., Terrien N., Urtizberea M., Pierson P., Bourre J. M. Immunotoxicothérapie: effet protecteur d'anticorps anticolchicine lors de l'intoxication aiguë chez le lapin et la souris. C.R. Acad. Sci. Paris 1986; 19: 661–664
   Google Scholar
• Schmidt D. H., Kaufman B. M., Butler V. P. Persistence of hapten-antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten. J. Exp. Med. 1974; 139: 278–294
   PubMed Web of Science ®Google Scholar
• Smith T. W., Lloyd B. L., Spicer N., Haber E. Immunogenecity and kinetics of distribution and elimination of sheep digoxinspecific IgG and Fab fragments in the rabbit and baboon. Clin. Exp. Immunol. 1979; 36: 384–396
   PubMed Web of Science ®Google Scholar
• Baud F. J., Sato S., Abuaf N., Scherrmann J. M., Bismuth C. Pharmacokinetics of sheep digitalis-specific Fab fragments in man. 2 cases. Toxicol. Letters 1986; 31: 153
   Google Scholar
• Schaumann W., Kaufmann B., Neubert P., Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur. J. Clin. Pharmacol. 1986; 30: 527–533
   PubMed Web of Science ®Google Scholar
• Brown L., Erdmann E. Binding of digitalis derivatives to beef, cat and human cardiac (Na+, K+)- ATPase. Affinity and kinetic constants. Arch. Int. Pharmacodyn. Ther. 1984; 271: 129–240
   Google Scholar
• Garlaud D. L. Kinetics and mechanism of colchicine binding to tubulin: evidence for ligand-induced conformational change. Biochemistry 1978; 17: 4266–4272
   PubMed Web of Science ®Google Scholar
• Ford A. R., Aronson J. K., Grahame-Smith D. G., Rose J. A. The characteristics of the binding of 12-α-(3H)- digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br. J. Clin. Pharmacol. 1978; 8: 115–124
   Web of Science ®Google Scholar
• Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokin. Biopharm. 1978; 6: 547–557
   PubMedGoogle Scholar
• Baud F., Bismuth C., Pontal P. G., Scherrmann J. M., Smith T. W. Time course of antidigoxin Fab fragments and plasma digitoxin concentrations in an acute digitalis intoxication. J. Toxicol. Clin. Toxicol. 1983; 19: 857–860
   Google Scholar
• Ochs H. R., Smith T. W. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. J. Clin. Invest. 1977; 60: 1303–1313
   PubMed Web of Science ®Google Scholar
• Thompson R. J., Jackson A. P. Cyclic complexes and high avidity antibodies. TIBS 1984; 9: 1–3
   Web of Science ®Google Scholar
• Matsumoto Y. I., Sugano T., Miyamoto C., Masuho Y. Generation of hybridomas producing human monoclonal antibodies against human cytomegalovirus. Biochem. Biophys. Res. Comm. 1986; 37: 273–280
   Google Scholar
• Gaffar S. A., Surch C. D., Glassy M. C. Variations in the secretion of monoclonal antibodies by human-human hybridomas. Hybridoma 1986; 5: 93–105
   PubMed Web of Science ®Google Scholar
• Stevenson G. T., Glennie M. J., Paul F. E., Stevenson F. K., Watts H. F., Wyeth P. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells. Bioscience Rep. 1985; 5: 991–998
   PubMed Web of Science ®Google Scholar
• Morrison S. Transfectomas provide novel chimeric antibodies. Science 1985; 229: 1202–1207
   PubMed Web of Science ®Google Scholar
• Gaffar S. A., Royston I., Glassy M. C. Strategies for the design and use of tumor-reactive human monoclonal antibodies. Bio Essays 1986; 4: 119–123
   PubMed Web of Science ®Google Scholar
• Padlan E. A., Cohen G. H., Davies D. R. Antibody Fab assembly: the interface residues between CH1 and CL. Molec. Immunol. 1986; 23: 951–960
   PubMed Web of Science ®Google Scholar
• Steiner L. A. Immunoglobulin disulfide bridges: theme and variations. Biosci. Rep. 1985; 5: 973–989
   PubMed Web of Science ®Google Scholar
• Van M. H.V. Regenmortel Which structural features determine protein antigenicity. TIBS 1986; 11: 36–39
   Web of Science ®Google Scholar
• Van Asbeck B. S., Hillen F. C., Boonen H. C.M., De Yong Y., Dormons J. A. M.A., Marx J. J.M. Death following paraquat intake in the rat is completely prevented by deferoxamine (Abstract). III World Congress of the World Federation of Association of Clinical Toxicology and Poison Control Centres, Brussels, August 27–30, 1986
   Google Scholar